Breast cancer
Results
Phase 2
This trial looked at capivasertib (AZD5363) with a hormone therapy drug called fulvestrant.
The trial was for women with breast cancer:
who were diagnosed after the menopause and
their cancer had spread into tissue surrounding the breast or to another part of the body
Cancer Research UK supported this trial.
This trial was open for women to join between 2015 and 2018. The results were published in 2020. The team published further results in 2022.
Recruitment start: 2 May 2014
Recruitment end: 5 March 2018
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sacha Howell Dr Robert Jones
AstraZeneca
Cancer Research UK
Cardiff University, Centre for Trials Research
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Velindre NHS Trust
This is Cancer Research UK trial number CRUK/12/044.
Last reviewed: 10 August 2022
CRUK internal database number: 10558